Information Provided By: 
Fly News Breaks for October 21, 2019
VRAY
Oct 21, 2019 | 16:20 EDT
Oppenheimer analyst Suraj Kalia initiated coverage of ViewRay with an Outperform rating and $7 price target. The promise of ViewRay's technology is in superior outcomes and lower toxicity, says Kalia, who estimates that 20%-30% of all medical linear accelerators placed within ten years will have magnetic resonance-guided capabilities. "We are in the first innings of a highly disruptive technology adoption curve," Kalia tells investors in a research note.
News For VRAY From the Last 2 Days
There are no results for your query VRAY
